Exhibit 10.14
ARCA BIOPHARMA , I NC .
F IRST A MENDMENT TO N OTE AND W ARRANT P URCHASE A GREEMENT
T HIS F IRST A MENDMENT TO N OTE AND W ARRANT P URCHASE A GREEMENT (this “ Amendment ”) is made
and entered into as of October 10, 2008 by and between ARCA
biopharma, Inc., a Delaware corporation (the “ Company
”), the undersigned Purchasers (individually, a “
Purchaser ” and collectively, the “
Purchasers ”) and Parent.
RECITALS
A. The Company has authorized
the sale of its 6% convertible promissory notes due March 31,
2009 and warrants to purchase shares of the Company’s capital
stock.
B. The Company and the
Purchasers have entered into that certain Note and Warrant Purchase
Agreement, dated September 24, 2008 (the “ Purchase
Agreement ”) pursuant to which the Purchasers agreed to
purchase the Notes at the Closing. Capitalized terms used, but not
defined herein, shall have the meanings assigned to them in the
Purchase Agreement.
C. Section 5.7 of the Purchase
Agreement allows the Company, a majority of the Principal Series
Preferred Stockholders (as such term is defined in the Restated
Charter) and, for so long as the Merger Agreement remains in full
force and effect, Parent, to amend the Purchase
Agreement.
D. The Company, the undersigned
Purchasers, who represent at least a majority of the Principal
Series Preferred Stockholders (as such term is defined in the
Restated Charter), and Parent, desire to amend the Purchase
Agreement as provided below.
AMENDMENT
NOW, THEREFORE, in consideration of
the above recitals and the mutual covenants contained herein, the
parties hereby agree as follows:
1. Section 1.2 of the Purchase
Agreement is hereby deleted in its entirety and replaced with the
following language:
1.2 Issuance of
Warrants. Subject to the terms of this
Agreement, and for the additional consideration (the “
Warrant Consideration ”) set forth opposite such
Purchaser’s name on the Schedule of Purchasers under the
heading “ Warrant Consideration ,” the Company
shall issue to each Purchaser a warrant to purchase shares of
Common Stock of the Company. Subject to certain adjustments
provided in the warrant, each warrant issuable pursuant to this
Section 1.2 shall entitle the Purchaser to acquire the number
of shares equal to the quotient of (a) one-fifth (
1 / 5 th
) of such
Purchaser’s total purchase price (“ Total Purchase
Price ”) set forth opposite such
1
Purchaser’s name on the
Schedule of Purchasers under the heading “ Total Purchase
Price ”) divided by (b) the exercise price of
each warrant, rounded up to the nearest share. The warrants shall
be in substantially the form attached hereto as Exhibit B
(each, a “ Warrant ” and collectively, the
“ Warrants ”).
2. Section 1.4 of the Purchase
Agreement is hereby deleted in its entirety and replaced with the
following language:
1.4 Delivery.
At the Closing: (a) each
Purchaser will deliver to the Company a check or wire transfer
funds in the total amount of such Purchaser’s Total Purchase
Price, (b) the Company shall issue and deliver to each
Purchaser a Note in favor of such Purchaser payable in the
principal amount of such Purchaser’s Loan Amount and a
Warrant, and (c) the Company shall execute and deliver such
other documents as the Purchasers shall reasonably require in order
to consummate the transactions contemplated herein. In connection
with the Closing, the Company shall have filed with the Delaware
Secretary of State the Certificate of Amendment to the Restated
Charter (as defined below) in substantially the form attached
hereto as Exhibit C (the “ Charter Amendment
”).
3. The Schedule of Purchasers
attached to the Purchase Agreement is hereby replaced in its
entirety with the Schedule of Purchasers attached hereto as
Exhibit A .
4. Except as expressly amended by
this Amendment, the Purchase Agreement shall remain in full force
and effect without change.
5. This Amendment may be executed in
any number of counterparts, each of which when executed and
delivered shall be an original, but all of which together shall
constitute one and the same instrument.
[signature pages follow]
2
I N W ITNESS W HEREOF , the
parties have executed this A MENDMENT as of the date first written above.
|
|
|
|
|
|
|
|
|
|
COMPANY:
|
|
|
|
PURCHASERS:
|
|
|
|
|
ARCA BIOPHARMA , I NC .
|
|
|
|
S
KYLINE V ENTURE P ARTNERS Q UALIFIED P URCHASER F UND IV, L.P.
|
|
|
|
|
|
|
Signature:
|
|
/s/ Christopher D.
Ozeroff
|
|
|
|
By:
|
|
Skyline Venture
Management IV, LLC
|
|
Print Name:
|
|
Christopher D.
Ozeroff
|
|
|
|
|
|
Its General
Partner
|
|
Title:
|
|
Executive Vice
President Business Development and General Counsel
|
|
|
|
By:
|
|
|
|
|
|
|
|
|
|
|
John G Freund,
Managing Director
|
|
|
|
|
|
|
|
|
|
|
I
NTER W EST P ARTNERS IX, LP
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
InterWest
Management Partners IX, LLC
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
|
|
|
|
|
Linda Grais,
Venture Member
|
|
|
|
|
|
|
|
|
|
|
A
TLAS V ENTURE F UND VII, L.P.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
Atlas Venture
Associates VII, L.P.
|
|
|
|
|
|
|
|
|
its General
Partner
|
|
|